Differential Risk of Cancer Associated with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Real-world Databases
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Background Glucagon-like peptide 1 receptor agonists (GLP1Ra) are commonly used in type 2 diabetes mellitus (T2DM). However, differential risk of various cancers among GLP1Ra recipients is unknown.Methods We inquired an aggregated electronic health record database, Explorys, and compared the adjusted odds ratio (aOR) of cancers between GLP1Ra and metformin users. Findings were validated in the FDA Adverse Event Reporting System (FDA FAERS).Results From 1/2005 to 6/2019, we identified 619 340 and 64 230 patients in the metformin and GLP1Ra group, respectively. Within 5 years of starting antidiabetic medications, GLP1Ra was associated with significantly lower incident risk of prostate (aOR 0.81, p = .03), lung (aOR 0.81, p = .05), and colon cancer (aOR 0.85, p = .03), while the risk of thyroid cancer was significantly higher (aOR 1.65, p < .01). Similar findings were seen in the FDA FAERS database, where GLP1Ra was associated with lower risk of prostate (aOR 0.72, p = .08), lung (aOR 0.52, p < .01), colon cancer (aOR 0.82, p = .31), and higher risk of thyroid cancer (aOR 4.33, p < .01). In addition, with longer duration of GLP1Ra use, the risk of prostate, lung, and colon cancer further decreased, suggesting an exposure duration–response relationship.Conclusions GLP1Ra is associated with lower risks of prostate, lung, and colon cancer, but higher risk of thyroid cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“which was also confirmed by analyses of serious adverse events reported to the US Food and Drug Administration (FDA) 11,13 and the World Health Organization's pharmacovigilance database Vigi-Base.12,14”
From Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials (2024) · cites this paper as [11]
In the citing paper
“Some retrospective observational studies detected an increased risk of thyroid cancer in association with GLP-1RA treatment, 11,12”
From Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials (2024) · cites this paper as [11]
Citations
Cites
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209 · cited 1×
“The concern for pancreatic cancer arises from increased incidence of pancreatitis in observational studies(13) and increased beta-cell mass in animal models.(16) While the topic remains controversial, most meta-analyses did not find an association between GLP1Ra and pancreatic cancer.”
BackgroundPancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 3×
“Similar methodology has been applied to study adverse events in FDA FAERS.13 Database Inquiry In Explorys, patients with T2DM were identified with both Systematized Nomenclature of Medicine (SNOMED) Clinical Term “Diabetes mellitus type 2” and Logical Observation Identifiers Names and Codes (LOINC) finding “Hemoglobin…”
MethodResultInfluentialPyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876 · cited 1×
“Moreover, GLP-1 receptors are also expressed at high levels in various tumors, such as pheochromocytoma, medullary thyroid carcinoma, meningioma, embryonic tumors, and prostate carcinomas.(2,4,5) Interestingly, in vitro studies and animal models showed that GLP-1 receptor activation could promote or inhibit tumor grow…”
BackgroundBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 2×
“It has been shown to enhance insulin secretion, inhibit gastric acid secretion, affect gut mobility, and induce satiety.1 Indeed, GLP-1 receptors have been identified in numerous tissues, including gastrointestinal (GI) tract, pancreatic islets, thyroid gland, kidney, heart, lungs, and central nervous system (CNS).2,3…”
MethodPancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 2×
“Indeed, GLP-1 receptors have been identified in numerous tissues, including gastrointestinal (GI) tract, pancreatic islets, thyroid gland, kidney, heart, lungs, and central nervous system (CNS).(2,3) Moreover, GLP-1 receptors are also expressed at high levels in various tumors, such as pheochromocytoma, medullary thyr…”
BackgroundGandini, S., Puntoni, M., Heckman-Stoddard, B. M., Dunn, B. K., Ford, L., DeCensi, A., & Szabo, E. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0424 · Cited by 457
Minireview: The Glucagon-Like Peptides
Drucker, D. J. (2001) · Endocrinology · doi:10.1210/en.142.2.521 · Cited by 421 · cited 1×
“It has been shown to enhance insulin secretion, inhibit gastric acid secretion, affect gut mobility, and induce satiety.(1) Indeed, GLP-1 receptors have been identified in numerous tissues, including gastrointestinal (GI) tract, pancreatic islets, thyroid gland, kidney, heart, lungs, and central nervous system (CNS).”
BackgroundPancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
(2014) · New England Journal of Medicine · doi:10.1056/nejmx140026 · Cited by 372
Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy
Parks, M., & Rosebraugh, C. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1001578 · Cited by 275
Research works printed but not linked: 3
- 10.1210/endo.142.2.7983 · doi:10.1210/endo.142.2.7983 · Paper page
- Li XN, 2017, Exp Clin Endocrinol Diabetes, 125, 91
- Ganini S, 2014, Cancer Prev Res, 72, 1013
Cited by
The expanding incretin universe: from basic biology to clinical translation
Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243
GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity
Dai, H., Li, Y., Lee, Y. A., Lu, Y., George, T. J., Donahoo, W. T., Lee, K. P., Nakshatri, H., Allen, J. M., Guo, Y. M., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.2681 · Cited by 124
Yang, Z., Lv, Y., Yu, M., Mei, M., Xiang, L., Zhao, S., & Li, R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.925377 · Cited by 120
“65) than metformin, and they also found similar association between these tumors and GLP-1RA in the FDA Adverse Event Reporting System (FAERS) database (Wang and Kim, 2022).”
BackgroundSilverii, G. A., Monami, M., Gallo, M., Ragni, A., Prattichizzo, F., Renzelli, V., Ceriello, A., & Mannucci, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15382 · Cited by 113
“10 Some retrospective observational studies detected an increased risk of thyroid cancer in association with GLP-1RA treatment, 11,12 which was also confirmed by analyses of serious adverse events reported to the US Food and Drug Administration (FDA) 11,13 and the World Health Organization's…”
InfluentialGLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
Wilbon, S. S., & Kolonin, M. G. (2023) · Cells · doi:10.3390/cells13010065 · Cited by 101
“…of thyroid cancer in GLP1RA-treated patients when compared to patients on metformin; however, the increased rate of thyroid cancer was not significant in the liraglutide-treated groups, showing that the cancer association may be drug-dependent and not a feature of the entire class of drugs [83].”
Background
Metadata
- Authors
- Wang, J., & Kim, C. H.
- Affiliations
- MetroHealth Medical Center (US)
- Corresponding author
- Kim, Chang H.
- ORCID
- Wang, Jiasheng
- Venue
- Endocrine Research
- Publisher
- Informa UK Limited
- Published
- 2021-08-30
- Volume
- 47
- Issue
- 1
- Pages
- 18-25
- ISSN
- 0743-5800 (ISSN-L)
- 1532-4206
- OpenAlex
- W3197313174
- Cited by
- 74
- References
- 29
- Citations by year
- 2026: 12 · 2025: 24 · 2024: 17 · 2023: 13 · 2022: 7 · 2021: 1
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- GLP-1 receptor agonists, cancer risk, type 2 diabetes, metformin, prostate cancer, lung cancer, colon cancer, thyroid cancer, adverse drug reactions, exposure duration, drug safety
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Male, Metformin, Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Differential Risk of Cancer Associated with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Real-world Databases. https://app.cochat.ai/papers/10.1080/07435800.2021.1955255
- The paper
- Wang, J., & Kim, C. H. (2022). Differential Risk of Cancer Associated with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Real-world Databases. Endocrine Research. https://doi.org/10.1080/07435800.2021.1955255
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.